Fig. 7.
![Fig. 7. PBL were activated with PHA (5 μg/mL) for 3 days. Viable cells were then treated by antibodies MoAb90 (10 μg/mL), YTH862 (10 μg/mL), or anti-Fas MoAb CH11 (1 μg/mL) alone or in association and measurements of apoptosis were performed as in Fig 6. In parallel, CD45RA and CD45RO phenotype after 3 days of culture was evaluated by FACS analysis (CD45RA+ 22 [2.4%], CD4RO+ 32 [0.5%], CD45RA+RO+ 32 [0.5%]) (SEM in brackets).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/90/9/10.1182_blood.v90.9.3629/4/bl_0035f7.jpeg?Expires=1735504606&Signature=bNVfYxRW70hdwLQAwdsY-sR4M-z~wtiDvwdGoGJCP0M08PlvDD1JSp4AjBUwPimpVlEckWAtyG6rEGHcbPxYOTyC4FM8zYf9HPlTUL95Dtx7P7fJ4c21er2yzT6ryMsp8flLsjFF4mLiuR8B5j0jMJF3nROHAts~kZykzksZlAZfJoAcTK1nhUc8qCKUXSe2HjxpgxYdbStGgt2hYmU3xNaSE9M4CBeIm2dNqXJNDKAP7b5nKyUKs59mYgMN6nhaeDRHr4HD-wNxCwz65NTbJ1QWUWExg6CYAtWZn8TGkULjkCxS9ne8Cv2OfQEGtXKW4XYYCTvYL6sYCzvA~wtfBQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PBL were activated with PHA (5 μg/mL) for 3 days. Viable cells were then treated by antibodies MoAb90 (10 μg/mL), YTH862 (10 μg/mL), or anti-Fas MoAb CH11 (1 μg/mL) alone or in association and measurements of apoptosis were performed as in Fig 6. In parallel, CD45RA and CD45RO phenotype after 3 days of culture was evaluated by FACS analysis (CD45RA+ 22 [2.4%], CD4RO+ 32 [0.5%], CD45RA+RO+ 32 [0.5%]) (SEM in brackets).
